Skip to content
value.today

High Throughput Genomics Inc.

Total raised
$46 M
7 rounds on record
Latest round
$8 M
Mar 2022
First round on record
Nov 2008
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of High Throughput Genomics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2022$8 MNo. 7$2 to $10 million

High Throughput Genomics Inc.: Raise no. 7, Mar 2022

Investors in this round

1 investor had bought by the notice of Mar 25, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $21 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$292,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Lubniewski · Executive Officer, Director
  • Shaun McMeans · Executive Officer
  • Ann F. Hanham · Director
  • Christopher R. Kiritsy · Director
  • Don M. Hardison · Director
  • Harry A. George · Director
  • James T. LaFrance · Director
  • Lee R. McCracken · Director
  • Michelle R. Griffin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cantor Fitzgerald & Co. (CRD 134) · New York, New YorkSold in NY

Remarks in the notice

  • On the amounts: “Includes amounts receivable by the Issuer upon the exercise of certain warrants to purchase common stock (assuming no cashless exercise).”

Signed by Shaun D. McMeans, SVP and CFO. Source: SEC Form D, newest notice filed Mar 25, 2022. Read the notice at the SEC.

equity, optionsSEC
Sep 2019$3 MNo. 6$2 to $10 million

High Throughput Genomics Inc.: Raise no. 6, Sep 2019

Investors in this round

2 investors had bought by the notice of Oct 1, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$207,809
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Lubniewski · Executive Officer, Director
  • Shaun B. McMeans · Executive Officer
  • Ann F. Hanham · Director
  • Don M. Hardison · Director
  • Harry A. George · Director
  • James T. LaFrance · Director
  • Lee R. McCracken · Director
  • Michelle R. Griffin · Director
  • Timothy B. Johnson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cantor Fitzgerald & Co. (CRD 134) · New York, New YorkSold in CA, OR

Remarks in the notice

  • On the amounts: “Total Amount Sold represents the amount received by the Issuer from the sale of pre-funded warrants to purchase common stock. Total Remaining to be Sold represents amount receivable by the Issuer upon cash exercise of such pre-funded warrants.”

Signed by Shaun D. McMeans, SVP Fin & Admin and CFO. Source: SEC Form D, newest notice filed Oct 1, 2019. Read the notice at the SEC.

optionsSEC
Feb 2014$7 MNo. 5$2 to $10 million

High Throughput Genomics Inc.: Raise no. 5, Feb 2014

Investors in this round

15 investors had bought by the notice of Feb 13, 2014: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $22 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shaun McMeans · Executive Officer
  • Timothy Johnson · Executive Officer, Director
  • Harry George · Director
  • Jim Weersing · Director
  • Larry Senour · Director
  • Molly Hoult · Director
  • Peter Bisgaard · Director
  • Simeon George · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount includes amounts receivable by the Issuer upon the exercise of warrants to purchase the Issuer's Series E Preferred Stock.”

Signed by Shaun McMeans, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 13, 2014. Read the notice at the SEC.

equity, optionsSEC
Nov 2012$8 MNo. 4$2 to $10 million

High Throughput Genomics Inc.: Raise no. 4, Nov 2012

Investors in this round

9 investors had bought by the notice of Nov 14, 2012: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $27 M offered; $19 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shaun W. McMeans · Executive Officer
  • Timothy Johnson · Executive Officer, Director
  • Donald W. Grimm · Director
  • Harry George · Director
  • Jim Weersing · Director
  • Larry Senour · Director
  • Molly W. Hoult · Director
  • Peter W. Bisgaard · Director
  • Simeon W. George · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shaun McMeans, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 14, 2012. Read the notice at the SEC.

equitySEC
Feb 2011$14 MNo. 3$10 to $50 million

High Throughput Genomics Inc.: Raise no. 3, Feb 2011

Investors in this round

30 investors had bought by the notice of Jun 17, 2011: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kirk A. Collamer · Executive Officer
  • Timothy Johnson · Executive Officer, Director
  • Donald W. Grimm · Director
  • Harry A. George · Director
  • Jim A. Weersing · Director
  • Larry A. Senour · Director
  • Molly W. Hoult · Director
  • Peter W. Bisgaard · Director
  • Simeon W. George · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kirk A. Collamer, VP and Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 17, 2011. Read the notice at the SEC.

equitySEC
Jul 2010$2 MNo. 2Under $2 million

High Throughput Genomics Inc.: Raise no. 2, Jul 2010

Investors in this round

22 investors had bought by the notice of Aug 6, 2010: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kirk A. Collamer · Executive Officer
  • Timothy Johnson · Executive Officer, Director
  • Bruce E. Seligmann · Director
  • Donald W. Grimm · Director
  • Harry M. George · Director
  • Jim A. Weersing · Director
  • John M. Holliman · Director
  • Larry E. Senour · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kirk A. Collamer, VP and Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 6, 2010. Read the notice at the SEC.

debt, optionsSEC
Nov 2008$4 MNo. 1$2 to $10 million

High Throughput Genomics Inc.: Raise no. 1, Nov 2008

Investors in this round

7 investors had bought by the notice of Jul 23, 2009: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series C-2 Convertible Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kirk A. Collamer · Executive Officer
  • Timothy Johnson · Executive Officer, Director
  • Bruce E. Seligmann · Director
  • Donald W. Grimm · Director
  • Harry George · Director
  • Jim Weersing · Director
  • John M. Holliman · Director
  • Larry Senour · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kirk A. Collamer, VP and Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 23, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • High Throughput Genomics Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2022).

    SEC Form D · Mar 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2022

That is all the official record says: High Throughput Genomics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in High Throughput Genomics Inc.
InvestorKindAmountRoundRoleSource
Debra A. GordonPersonnot statednot statedHeld Series D and E preferred stock (Form 3, 2015)SEC Form 3
Fletcher Spaght Ventures II LPVenture capitalnot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
FSV II-B LPFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
FSV II LPFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
GSK PLCFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
John L. LubniewskiPersonnot statednot statedHeld Series D and E preferred stock (Form 3, 2015)SEC Form 3
Merck Capital Ventures LLCVenture capitalnot statednot statedHeld Series C-1, C-2, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Shaun D. McMeansPersonnot statednot statedHeld Series D and E preferred stock (Form 3, 2015)SEC Form 3
Tim B. JohnsonPersonnot statednot statedHeld Series C-2, D and E preferred stock, director (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 30 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by High Throughput Genomics Inc.
NameRoleNamed in
John LubniewskiExecutive officerMar 2022
Shaun McMeansExecutive officerMar 2022
Shaun B. McMeansExecutive officerOct 2019
Timothy JohnsonExecutive officerFeb 2014
Shaun W. McMeansExecutive officerNov 2012
Kirk A. CollamerExecutive officerJun 2011
Ann F. HanhamDirectorMar 2022
Christopher R. KiritsyDirectorMar 2022
Don M. HardisonDirectorMar 2022
Harry A. GeorgeDirectorMar 2022
James T. LaFranceDirectorMar 2022
John LubniewskiDirectorMar 2022
Lee R. McCrackenDirectorMar 2022
Michelle R. GriffinDirectorMar 2022
Timothy B. JohnsonDirectorOct 2019
Harry GeorgeDirectorFeb 2014
Jim WeersingDirectorFeb 2014
Larry SenourDirectorFeb 2014
Molly HoultDirectorFeb 2014
Peter BisgaardDirectorFeb 2014
Simeon GeorgeDirectorFeb 2014
Timothy JohnsonDirectorFeb 2014
Donald W. GrimmDirectorNov 2012
Molly W. HoultDirectorNov 2012
Peter W. BisgaardDirectorNov 2012
Simeon W. GeorgeDirectorNov 2012
Jim A. WeersingDirectorJun 2011
Larry A. SenourDirectorJun 2011
Bruce E. SeligmannDirectorAug 2010
Harry M. GeorgeDirectorAug 2010
John M. HollimanDirectorAug 2010
Larry E. SenourDirectorAug 2010